Objectives The efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer
(NSCLC) patients with pre-existing interstitial lung disease (ILD) is unclear. Materials and …

Immune checkpoint inhibitor (ICI) treatment has become an important therapeutic option for
various cancer types. Although the treatment is effective, ICI can overstimulate the patient's …

Abstract The ACR Incidental Findings Committee presents recommendations for managing
incidentally detected lung findings on thoracic CT. The Chest Subcommittee is composed of …

Interstitial lung abnormalities (ILA), incidental findings on computed tomography scans, have
raised concerns due to their association with worse clinical outcomes. Our meta-analysis …

This review aims to provide an understanding of the diagnostic and therapeutic challenges
of uveitis associated with immune checkpoint inhibitors (ICI). In the wake of these molecules …

Abstract Background Immune checkpoint inhibitors (ICIs) have demonstrated efficacy over
previous cytotoxic chemotherapies in clinical trials among various tumors. Despite their …

The emergence of tyrosine kinase inhibitors and immune checkpoint inhibitors has paved a
new era for the management of non‐small cell lung cancer, which has for many years lacked …

Objective To assess the prognostic significance of automatically quantified interstitial lung
abnormality (ILA) according to the definition by the Fleischner Society in patients with …

Background Immune checkpoint inhibitors (ICIs) are widely used in cancers with or without
other treatments. Immune-related adverse events (irAEs) have been reported as side effects …

Simple Summary Interstitial pneumonia (IP) represents a significant prognostic comorbidity
in patients diagnosed with non-small-cell lung cancer (NSCLC). Even if treatment for lung …